Trials / Completed
CompletedNCT00721734
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carfilzomib | Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute. |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2008-07-24
- Last updated
- 2017-05-02
- Results posted
- 2015-12-09
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00721734. Inclusion in this directory is not an endorsement.